Current status of immune checkpoint inhibition in early-stage NSCLC

J. Vansteenkiste*, E. Wauters, B. Reymen, C. J. Ackermann, S. Peters, D. De Ruysscher

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)1244-1253
Number of pages10
JournalAnnals of Oncology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • immunotherapy
  • non-small-cell lung cancer
  • early stage
  • clinical trials
  • CELL-LUNG-CANCER
  • STEREOTACTIC ABLATIVE RADIOTHERAPY
  • TUMOR-REGRESSION
  • PHASE-II
  • RADIATION
  • IMMUNOTHERAPY
  • CHEMOTHERAPY
  • BLOCKADE
  • IRRADIATION
  • IPILIMUMAB

Cite this